Site-Specific HER2 Antibody Drug Conjugates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant clinical need for developing further HER2-directed cancer therapies for patients with HER2-overexpressing tumors that do not respond, respond poorly, or become resistant to existing treatments like Herceptin and Kadcyla.
Innovation Solution
Site-specific HER2 antibody drug conjugates (ADCs) are developed, which enable targeted delivery of therapeutics to cancer cells by conjugating a drug to a HER2-binding antibody through specific linkers at engineered residues, maintaining antigen binding capability and reducing off-target toxicities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional non-site-specific ADCs are used, then manufacturing is simpler, but manufacturing precision and homogeneity of drug:antibody ratios are poor
Solution Approach 1:
The conjugation process is segmented into two distinct steps: first, site-specific incorporation of non-canonical amino acids (ncAAs) with unique functional groups into the antibody at defined positions; second, selective conjugation of drug linkers to these ncAA sites. This segmentation enables homogeneous drug:antibody ratios (DAR) while maintaining manageable process complexity through modular methodology.
Solution Approach 2:
The invention introduces local quality by placing specific functional groups (ncAAs) at predetermined locations within the antibody structure. This allows site-specific conjugation at defined residues rather than random lysine or cysteine sites, achieving uniform DAR (e.g., DAR=2, 3, or 4) and improving manufacturing precision without requiring complete redesign of the entire conjugation process.
2Manufacturing precision
If site-specific conjugation is implemented, then manufacturing precision of drug:antibody ratios is improved, but device complexity increases
Solution Approach 1:
The methodology employs preliminary action by pre-installing ncAAs with orthogonal functional groups into the antibody at desired sites before drug conjugation. This preparatory step creates predetermined attachment points that simplify the subsequent drug conjugation process, achieving uniform DAR while the initial ncAA incorporation can be performed using established protein engineering techniques.
Solution Approach 2:
The invention changes the chemical parameter of the antibody by incorporating ncAAs with unique functional groups (e.g., azide, alkyne, keto) that are absent in natural antibodies. This parameter change enables selective conjugation chemistry specific to these functional groups, achieving site-specific and homogeneous drug:antibody ratios while allowing flexibility in choosing different ncAA types for different conjugation strategies.
3Reliability
If existing HER2 therapies are used, then treatment is available, but reliability is poor due to resistance development
Solution Approach 1:
The invention creates a universal platform for HER2-targeted ADCs that can deliver different cytotoxic payloads through site-specific conjugation. The core technology (ncAA incorporation at defined antibody sites) remains universal, while allowing adaptation to different drug linkers and payloads. This multi-functional platform can address multiple resistance mechanisms and tumor types expressing HER2, improving reliability without requiring completely separate ADC developments.
Solution Approach 2:
The invention enables parameter changes in the ADC structure by varying the cytotoxic payload, linker type, and ncAA position while maintaining the same site-specific conjugation methodology. This allows optimization of pharmacokinetic properties, tumor penetration, and resistance overcoming by adjusting these parameters rather than developing entirely new antibodies, thereby improving reliability against resistant tumors.
Data Source
AI summary
The present invention provides site specific HER2 antibody drug conjugates and methods for preparing and using the same.